Viemed Q2 Revenue Climbs 24% to $78.1M, but Higher Costs Weigh on Net Income; Medicare Overpayment Dispute Narrows to $2.2M
VMD sits 85% above its 52-week low of $5.93.
Summary
Viemed Healthcare reported Q2 2026 revenue of $78.1 million, up 24% year-over-year and matching consensus, but net income fell to $2.76 million. The company also disclosed a $2.2 million Medicare overpayment dispute following an unfavorable ALJ ruling.
Key Events · Earnings and Guidance · VMD
-
Q2 Revenue Up 24% to $78.1M
Revenue reached $78.1 million, driven by a record ventilator patient census of 12,635 and a near-doubling of equipment and supply sales to $19.0 million, largely from women's health products.
-
Net Income Declines 12% to $2.76M
Net income attributable to Viemed fell to $2.76 million from $3.16 million a year ago, as SG&A expenses grew 29% and a prior-year $0.6 million gain on equipment sales reversed to a $0.6 million loss.
-
Medicare Audit Overpayment Reduced to $2.2M, Unfavorable ALJ Ruling
The asserted overpayment from a Medicare audit was reduced from $5.9 million to $2.2 million on appeal, but an administrative law judge issued an unfavorable decision in June 2026. Viemed intends to pursue further appeals and has not accrued a loss.
-
Active Share Repurchases Continue
The company repurchased 680,802 shares for $6.5 million during the first half of 2026 under its new repurchase program, with 1.25 million shares remaining authorized.
Analysis · VMD · Industrial Applications And Services
Record Q2 revenue of $78.1 million—a 24% year-over-year increase—was fueled by growth in ventilator patients and women's health sales. Yet net income attributable to Viemed slipped 12% to $2.76 million, as selling, general and administrative expenses outpaced revenue growth and a prior-year gain on equipment sales did not recur. Adding to the mixed picture, an administrative law judge ruled unfavorably in the company's Medicare audit case, leaving a disputed overpayment of $2.2 million that Viemed plans to appeal further. While the top-line momentum and record patient census are encouraging, margin pressure and the unresolved regulatory matter cloud the quarter.
At the time of this filing, VMD was trading at $11.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $448.2M. The 52-week trading range was $5.93 to $12.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.